Nicotinamide treatment in a murine model of familial tumoral calcinosis reduces serum Fgf23 and raises heart calcium

Bone

Volumn 67, Issue , 2014, Pages 139-144

  Reilly, Austin M ^a   Gray, Amie K ^a   Moe, Sharon M ^a,b   Ichikawa, Shoji ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Calcification; Fgf23; Nicotinamide; Phosphate; Tumoral calcinosis

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CREATININE; FIBROBLAST GROWTH FACTOR 23; NICOTINAMIDE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHORUS; FIBROBLAST GROWTH FACTOR; N ACETYLGALACTOSAMINYLTRANSFERASE; POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CALCIUM URINE LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE URINE LEVEL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; TISSUE LEVEL; TUMOR CALCINOSIS; URINARY EXCRETION; ANIMAL; BLOOD; CALCINOSIS; GENETICS; METABOLISM;

ANIMALS; CALCINOSIS; CALCIUM; FIBROBLAST GROWTH FACTORS; MALE; MICE; N-ACETYLGALACTOSAMINYLTRANSFERASES; NIACINAMIDE;

EID: 84904466137     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.06.036     Document Type: Article

References (30)

1. Topaz O., Shurman D.L., Bergman R., Indelman M., Ratajczak P., Mizrachi M., et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 2004, 36:579-581.
2. Ichikawa S., Baujat G., Seyahi A., Garoufali A.G., Imel E.A., Padgett L.R., et al. Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. Am J Med Genet A 2010, 152A:896-903.
3. Ichikawa S., Lyles K.W., Econs M.J. A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. J Clin Endocrinol Metab 2005, 90:2420-2423.
4. Ichikawa S., Imel E.A., Kreiter M.L., Yu X., Mackenzie D.S., Sorenson A.H., et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 2007, 117:2684-2691.
5. Benet-Pagès A., Orlik P., Strom T.M., Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005, 14:385-390.
6. Larsson T., Yu X., Davis S.I., Draman M.S., Mooney S.D., Cullen M.J., et al. A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab 2005, 90:2424-2427.
7. Kato K., Jeanneau C., Tarp M.A., Benet-Pages A., Lorenz-Depiereux B., Bennett E.P., et al. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 2006, 281:18370-18377.
8. Kurosu H., Ogawa Y., Miyoshi M., Yamamoto M., Nandi A., Rosenblatt K.P., et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006, 281:6120-6123.
9. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444:770-774.
10. Shimada T., Mizutani S., Muto T., Yoneya T., Hino R., Takeda S., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001, 98:6500-6505.
11. Ichikawa S., Guigonis V., Imel E.A., Courouble M., Heissat S., Henley J.D., et al. Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab 2007, 92:1943-1947.
12. Ichikawa S., Imel E.A., Sorenson A.H., Severe R., Knudson P., Harris G.J., et al. Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene. J Clin Endocrinol Metab 2006, 91:4472-4475.
13. Bergwitz C., Banerjee S., Abu-Zahra H., Kaji H., Miyauchi A., Sugimoto T., et al. Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis. J Clin Endocrinol Metab 2009, 94:4267-4274.
14. Dumitrescu C.E., Kelly M.H., Khosravi A., Hart T.C., Brahim J., White K.E., et al. A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features. Osteoporos Int 2009, 20:1273-1278.
15. Garringer H.J., Fisher C., Larsson T.E., Davis S.I., Koller D.L., Cullen M.J., et al. The role of mutant UDP-N-acetyl-alpha-d-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis. J Clin Endocrinol Metab 2006, 91:4037-4042.
16. Yamaguchi T., Sugimoto T., Imai Y., Fukase M., Fujita T., Chihara K. Successful treatment of hyperphosphatemic tumoral calcinosis with long-term acetazolamide. Bone 1995, 16:247S-250S.
17. Eto N., Miyata Y., Ohno H., Yamashita T. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant 2005, 20:1378-1384.
18. Katai K., Tanaka H., Tatsumi S., Fukunaga Y., Genjida K., Morita K., et al. Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 1999, 14:1195-1201.
19. Wu K.I., Bacon R.A., Al-Mahrouq H.A., Kempson S.A. Nicotinamide as a rapid-acting inhibitor of renal brush-border phosphate transport. Am J Physiol 1988, 255:F15-F21.
20. Kempson S.A., Colon-Otero G., Ou S.Y., Turner S.T., Dousa T.P. Possible role of nicotinamide adenine dinucleotide as an intracellular regulator of renal transport of phosphate in the rat. J Clin Invest 1981, 67:1347-1360.
21. Cheng S.C., Young D.O., Huang Y., Delmez J.A., Coyne D.W. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 2008, 3:1131-1138.
22. Takahashi Y., Tanaka A., Nakamura T., Fukuwatari T., Shibata K., Shimada N., et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 2004, 65:1099-1104.
23. Young D.O., Cheng S.C., Delmez J.A., Coyne D.W. The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Perit Dial Int 2009, 29:562-567.
24. Shahbazian H., Zafar Mohtashami A., Ghorbani A., Abbaspour M.R., Belladi Musavi S.S., Hayati F., et al. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial. Nefrologia 2011, 31:58-65.
25. Ichikawa S., Sorenson A.H., Austin A.M., Mackenzie D.S., Fritz T.A., Moh A., et al. Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression. Endocrinology 2009, 150:2543-2550.
26. Ichikawa S., Austin A.M., Gray A.K., Allen M.R., Econs M.J. Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosis. Endocrinology 2011, 152:4504-4513.
27. Bachmanov A.A., Reed D.R., Beauchamp G.K., Tordoff M.G. Food intake, water intake, and drinking spout side preference of 28 mouse strains. Behav Genet 2002, 32:435-443.
28. Ichikawa S., Gray A.K., Padgett L.R., Reilly A.M., Unsicker T.R. High dietary phosphate intake induces development of ectopic calcifications in a murine model of familial tumoral calcinosis. J Bone Miner Res 2014.
29. Budoff M.J., Young R., Lopez V.A., Kronmal R.A., Nasir K., Blumenthal R.S., et al. Progression of coronary calcium and incident coronary heart disease events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2013, 61:1231-1239.
30. Julius U., Fischer S. Nicotinic acid as a lipid-modifying drug-a review. Atheroscler Suppl 2013, 14:7-13.